Back

Age-related differences in efficacy of cardioneuroablation in patients with functional bradyarrhythmias

1 April 2025 (10:53 - 11:02)
Organised by: Logo
Congress Presentation Part of: Autonomic nervous system and cardiac arrhythmias Treatment EHRA Premium Access EHRA 2025 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Piotr Kulakowski

The Medical Centre of Postgraduate Education, Grochowski Hospital, Warsaw (Poland)

6 More presentations in this session

Presentation thumbnail
Cardioneuroablation in pediatric patients with cardioinhibitory vasovagal syncope, functional sinus bradycardia or functional advanced atrioventricular block
Professor P. Kulakowski (Warsaw, PL)
Abstract Slides Video
Presentation thumbnail
Effects of cardioneuroablation on exercise performance in patients with reflex asystolic syncope-preeliminary results.
Professor P. Kulakowski (Warsaw, PL)
Abstract Slides Video
Presentation thumbnail
Cardiac autonomic regulations after right-atrial versus bi-atrial ablation of superior paraseptal ganglion plexus: randomized study guided by ablation index
Doctor P. Stojadinovic (Prague, CZ)
Abstract Slides Video
Presentation thumbnail
Endocardial ablation of ganglionated plexus for the treatment of carotid sinus syndrome
Doctor C. Minguito Carazo (A Coruna, ES)
Abstract Slides Video
Presentation thumbnail
New insights from repeated extra-cardiac vagal nerve stimulation after recent successful cardioneuroablation in high risk patients with vagally-mediated bradyarrhythmias.
Professor S. Stec (Cracow, PL)
Abstract Slides Video

Access the full session

Session thumbnail
Autonomic nervous system and cardiac arrhythmias
Video

The Event

Event poster

EHRA 2025

1 April 2025 10:53 CET
You may be interested in
thumbnail
Congress Presentation
How to manage patients with bradycardic phenotype: pace or ablate or...?
thumbnail
Congress Presentation
Clinical outcomes of cardioneuroablation: what does the evidence tell us?
thumbnail
Congress Presentation
Cardioneuroablation experience for the treatment of vagally-mediated bradyarrhythmias

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources